{"id":"tild","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Sun Pharmaceutical Industries Limited","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Upper respiratory infections","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Injection site reactions","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Pain in extremity","drugRate":"0.5%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Angioedema","drugRate":"","severity":"serious"},{"effect":"Urticaria","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"company":"Sun Pharmaceutical Industries Limited","patents":[],"pricing":[],"allNames":["tild"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"target":"Interleukin-23","modality":"Small Molecule","explanation":"Imagine your body's cells have locks on them, and tild is a key that fits into one of those locks. When tild binds to its target, it can either block or enhance the activity of that target, which can help to treat a particular disease or condition. This is a simplified explanation of how small molecules like tild work.","oneSentence":"Tild is a small molecule that works by interacting with a specific target in the body.","technicalDetail":"Tild's mechanism of action is not well understood, but it is believed to involve the modulation of a specific protein or receptor in the body."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=tild","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tild","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:29:26.587157","biosimilars":[],"competitors":[],"genericName":"tild","indications":{"approved":[{"name":"Plaque psoriasis","diseaseId":"plaque-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04314531","phase":"PHASE3","title":"Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-07-01","conditions":["Active Psoriatic Arthritis"],"enrollment":296,"completionDate":"2026-04"},{"nctId":"NCT04991116","phase":"PHASE3","title":"Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2022-06-30","conditions":["Psoriatic Arthritis"],"enrollment":529,"completionDate":"2029-04"},{"nctId":"NCT04314544","phase":"PHASE3","title":"Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-07-01","conditions":["Active Psoriatic Arthritis"],"enrollment":508,"completionDate":"2025-12-22"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Sun Pharmaceutical Industries Limited","relationship":"Original Developer"}],"publicationCount":15,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"originalDeveloper":"Sun Pharmaceutical Industries Limited","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"TILD","companyName":"Sun Pharmaceutical Industries Limited","companyId":"sun-pharmaceutical-industries-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tild is a small molecule drug developed by Sun Pharmaceutical Industries Limited. However, there is limited information available about its target, drug class, and approved indications. As a result, it is difficult to provide a comprehensive summary of its mechanism of action and clinical use. Further research is needed to understand the properties and potential applications of tild. Its commercial status and safety considerations also remain unclear.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}